10-Q · May 12, 2026
Prelude Therapeutics reported revenue of $4.58 million for Q1 2026, driven by an Exclusive Option Agreement with Incyte. The company's diluted EPS improved significantly from -$0.42 in Q1 2025 to -$0.13, reflecting a…
Earnings analysis · 10-Q
PRLD earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The extracted portion of Prelude Therapeutics’ June 30, 2026 Form 10-Q contains no income statement, balance sheet, cash-flow, segment, or quantitative guidance data, so period-over-period financial trends cannot be…
Read full summary
The extracted portion of Prelude Therapeutics’ June 30, 2026 Form 10-Q contains no income statement, balance sheet, cash-flow, segment, or quantitative guidance data, so period-over-period financial trends cannot be assessed from the available filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. The filing does not update the risk-factor framework from the 2025 Form 10-K filed March 10, 2026, while reiterating ongoing litigation and clinical-stage investment risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Remain Effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
No Material Control Changes
Management reported no changes in internal control over financial reporting during the fiscal quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
-
No New Unregistered Securities
The company reported that it did not issue or sell any previously undisclosed unregistered securities during the three months ended June 30, 2026.
What to watch
-
Core Clinical-Stage Risks Remain
The filing states that investing in the common stock involves a high degree of risk and directs investors to the risk factors in the 2025 Annual Report filed March 10, 2026; no new or amended risk factors are identified in this 10-Q.
-
Potential IP and Litigation Exposure
Although management says it is not presently party to litigation expected to have a material adverse effect, the company notes that litigation can still create defense and settlement costs, management-resource diversion, negative publicity, and reputational harm.
-
Limited Market-Risk Disclosure
As a smaller reporting company, Prelude is not required to provide quantitative and qualitative market-risk disclosures for the period ending June 30, 2026, limiting visibility into market-risk exposures.
Management's outlook
The extracted 10-Q text does not provide quantitative revenue or EPS guidance, nor a new qualitative outlook. Numeric outlook may be deferred to the earnings press release or call.
Earlier filings 4
10-K · March 10, 2026
Prelude positions itself as a precision-oncology biotech focused on novel modalities (kinase inhibitors, targeted protein degraders, precision ADCs) and emphasizes internal discovery + selective partnering to advance…
10-Q · November 12, 2025
Prelude reported Q3 2025 revenue of $6.5M (up from $3.0M in Q3 2024) and a narrower net loss of $19.7M (EPS -$0.26) versus a net loss of $32.3M (EPS -$0.43) in Q3 2024. Operating expenses declined as R&D fell to…
10-Q · May 6, 2025
Prelude reported a net loss of $32,085,000 (GAAP) for the quarter ended March 31, 2025, or $(0.42) per share, essentially unchanged versus $(0.42) in Q1 2024. Cash, cash equivalents, restricted cash and marketable…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.